FDA EIR - MMC HEALTHCARE LTD. - March 30, 2024

An FDA inspection was conducted at MMC HEALTHCARE LTD., a manufacturer of human and animal drugs, from March 25 to March 30, 2024. The inspection's primary objective was to assess the firm's compliance with federal drug manufacturing regulations, particularly regarding Good Manufacturing Practices (GMP). The inspection identified significant violations, leading the FDA to classify the inspection with an Official Action Indicated (OAI) conclusion. This designation signifies that objectionable conditions were found which may lead to regulatory action. Specifically, the report notes a recommendation for a Warning Letter due to these observed GMP deficiencies. An FDA Form 483, documenting the specific violations observed, was issued to MMC HEALTHCARE LTD. Addressing these deficiencies requires the company to implement comprehensive corrective and preventive actions to ensure the quality and safety of its drug products. The FDA has prioritized a re-inspection, with specific follow-up dates (e.g., July 1, 2024) indicated to verify the satisfactory resolution of these critical issues and ensure full regulatory compliance.